Helix has released a new suite of pharmacogenomics (PGx) tests, widening its portfolio in neurology and oncology.

Nuravax and others are working on the next wave of Alzheimer’s treatments to catch the disease before symptoms arise.

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Lending support to his choice, Rocket Companies, on May 8, posted better-than-expected quarterly sales. Markets expect rate ...

Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Here are two ways in ...

The Lumipulse blood test became the first “in vitro diagnostic device” to be endorsed by the U.S. Food and Drug ...

The FDA approved a test that can help clinicians diagnose Alzheimer's disease early on using a simple blood draw. The test ...

The stock market volatility will only worsen as the U.S. continues to threaten its trade partners with tariffs. Investors do ...

Eli Lilly says a new starting dose regimen for its Alzheimer's disease therapy Kisunla reduces the risk of side effects that have stood in the way of approvals and reimbursement decisions for ...

In particular, the organisation is unhappy with Kennedy's repeated assertions that Alzheimer's research has been dedicated to ...

Zacks highlights LLY, GE, and AMGN as top picks, citing strong demand, product pipelines, and defense tailwinds despite some ...

Helix, a leader in precision health, is announcing the release of a new suite of pharmacogenomics (PGx) tests, including a test designed to identify patients with DYPD gene variants who may be at ...